Antigen-presenting cells infected by MVA-hHBV via cell-surface attachment factors

Antigen-presenting cells infected by MVA-hHBV via cell-surface attachment factors refers to a critical step in the mechanism of action of therapeutic vaccines designed to treat chronic Hepatitis B Virus (HBV) infection. Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that lacks the ability to replicate in human cells but can efficiently transduce them (Altenburg et al., 2014, Genes). The virus utilizes cell-surface attachment factors, primarily heparan sulfate proteoglycans (HSPGs) and chondroitin sulfate, to bind to the surface of professional antigen-presenting cells (APCs) such as dendritic cells (Chung et al., 1998, J. Virol.). Once the MVA-hHBV vector enters the APC, it expresses HBV-specific antigens (typically a fusion of Polymerase, Core, and Surface proteins), which are then processed and presented on MHC Class I and II molecules (Martin et al., 2015, Gut). This process is intended to overcome the immune tolerance characteristic of chronic HBV by priming and expanding a multi-specific T-cell response. Drugs utilizing this mechanism, such as TG1050, aim to achieve a functional cure by reducing viral load and inducing HBsAg seroconversion (Zoulim et al., 2020, J. Hepatol.).

Other names

MVA-hHBV infected APCsMVA-HBV transduction of antigen-presenting cellsTG1050 mechanism of action

Viral vector-mediated delivery of HBV antigens to antigen-presenting cells to induce T-cell mediated immunity.